The 28-day all cause mortality in patients by Leiden mutation status in the PROWESS study by treatment
FV Leiden status . | Total no. of patients . | No. of patients who died . | 28-d all cause mortality, % . | Relative risk of death (95% Cl) . |
|---|---|---|---|---|
| Negative | ||||
| Placebo group | 768 | 238 | 31.0 | 0.80 (0.68-0.94) |
| rhAPC group | 768 | 190 | 24.7 | |
| Positive | ||||
| Placebo group | 32 | 5 | 15.6 | 0.78 (0.23-2.63) |
| rhAPC group | 33 | 4 | 12.1 |
FV Leiden status . | Total no. of patients . | No. of patients who died . | 28-d all cause mortality, % . | Relative risk of death (95% Cl) . |
|---|---|---|---|---|
| Negative | ||||
| Placebo group | 768 | 238 | 31.0 | 0.80 (0.68-0.94) |
| rhAPC group | 768 | 190 | 24.7 | |
| Positive | ||||
| Placebo group | 32 | 5 | 15.6 | 0.78 (0.23-2.63) |
| rhAPC group | 33 | 4 | 12.1 |
Breslow-Day interaction P = .981.